BioXcel (BTAI) Form 4: Javier Rodriguez RSU Vesting Details
Rhea-AI Filing Summary
Javier Rodriguez, identified as Chief Legal Officer, Senior Vice President and Corporate Secretary of BioXcel Therapeutics, Inc. (BTAI), filed a Form 4 reporting transactions on September 14, 2025 and September 15, 2025. The filing discloses restricted stock unit activity tied to two prior grants: 521 RSUs awarded on March 14, 2022, and 562 RSUs awarded on March 15, 2023, each granted with time-based vesting schedules.
The tables show derivative and non-derivative entries reflecting 33 and 35 underlying shares associated with the reported transactions and list the number of vested RSU shares as 163 and 317 respectively in the derivative-security section. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on September 16, 2025.
Positive
- None.
Negative
- None.
Insights
TL;DR: Routine insider reporting of RSU vesting by a senior officer; disclosure aligns with standard Section 16 requirements and shows no extraordinary events.
The filing documents scheduled vesting activity from two previously granted RSU awards and records share deliverables on two consecutive dates in September 2025. This is a compliance-focused disclosure that satisfies transparency obligations for officer compensation realization. There is no indication of open-market purchases or sales, no change in control actions, and no extraordinary compensation modification disclosed in the Form 4.
TL;DR: Vesting of time-based RSUs from 2022 and 2023 grants produced small share deliveries; this reflects scheduled compensation vesting.
The explanatory notes confirm standard time-based vesting: 25% on the first anniversary and subsequent quarterly vesting at 6.25% increments. The reported underlying share amounts (33 and 35) are consistent with partial vesting events from the two grants. The disclosure helps reconcile awarded vs. vested RSUs but contains no performance-based acceleration or amendment details.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 35 | $0.00 | -- |
| Exercise | Common Stock | 35 | $0.00 | -- |
| Exercise | Restricted Stock Units | 33 | $0.00 | -- |
| Exercise | Common Stock | 33 | $0.00 | -- |
Footnotes (1)
- Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
